Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Three Markets to Watch Next Week (13.11.2026)
US Open: Wall Street tries to recover as Nvidia and Fed uncertainty weigh on sentiment
Economic Calendar: U.S. PPI inflation takes center stage. What will today's session bring❓
Morning Wrap - Will the markets recover from the scandal involving Nvidia's ousted CEO❓